Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Climb Bio, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
CLYM
Nasdaq
2830
eliemtx.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Climb Bio, Inc.
Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
- Feb 4th, 2025 12:00 pm
Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy
- Jan 9th, 2025 12:00 pm
Climb Bio to be Added to the Nasdaq Biotechnology Index
- Dec 19th, 2024 12:00 pm
Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights
- Nov 12th, 2024 9:05 pm
Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board
- Nov 11th, 2024 12:00 pm
Climb Bio to Present at Upcoming Investor Conferences
- Oct 31st, 2024 11:00 am
Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event
- Oct 15th, 2024 11:00 am
Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024
- Oct 11th, 2024 4:30 pm
Climb Bio to Host Virtual Investor Event on October 15, 2024
- Oct 3rd, 2024 2:00 pm
Eliem Therapeutics Changes Name to Climb Bio
- Oct 2nd, 2024 11:04 pm
Scroll